A single center, open-label, fixed sequence, two-period study to investigate the effect of memantine on pharmacokinetics, safety and tolerability of RO5313534 after single dose administration in healthy volunteers and the effect of RO5313534 on safety and tolerability of steady state memantine

Trial Profile

A single center, open-label, fixed sequence, two-period study to investigate the effect of memantine on pharmacokinetics, safety and tolerability of RO5313534 after single dose administration in healthy volunteers and the effect of RO5313534 on safety and tolerability of steady state memantine

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs RG 3487 (Primary) ; Memantine
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 18 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Mar 2011 Planned End Date changed from 1 Dec 2010 to 1 Mar 2011.
    • 15 Oct 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top